The Ensign Group (EGB) AI Stock Analysis

The Ensign Group

(XETRA:EGB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and earnings growthStrong revenue and earnings growth, reinforced by raised full-year guidance, indicates expanding demand and effective operating execution. If sustained, this growth can increase internal funding for acquisitions, technology and facility improvements while strengthening Ensign’s competitive position over the next several quarters.

Negative Factors

Margin compressionRecent gross and operating margin pressure suggests that revenue growth is not translating into earnings at the same rate as before. If costs or unfavorable mix remain elevated, profitability and cash available for reinvestment could be constrained despite continued top-line expansion.

The Ensign Group (EGB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.59B
Dividend Yield: 0.14%
Average Volume (3M): 29
Price to Earnings (P/E): 26.3
Beta (1Y): 0.06
Revenue Growth: 11.83%
EPS Growth: 13.89%
Country: Germany
Employees: 46,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

The Ensign Group Business Overview & Revenue Model

Company Description

The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Est...

The Ensign Group Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:8.57%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was strongly positive, supported by double-digit revenue and earnings growth, higher 2026 guidance, broad-based occupancy and skilled-mix gains, above-market clinical outcomes, substantial acquisition activity, and significant balance-sheet capacity. Management also highlighted ongoing AI and technology investments and a large acquisition pipeline. The main challenges were concentrated in newly acquired turnaround operations, particularly in Florida and Texas, which have below-average occupancy, clinical, financial, and physical-plant issues and are expected to take a year or more to contribute. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Strong Third-Quarter Financial Performance

GAAP diluted earnings per share was $1.76, an increase of 23.9%; adjusted diluted earnings per share was $2.03, an increase of 23.8%; consolidated GAAP and adjusted revenue were both $1.48 billion, an increase of 14.5%; GAAP net income was $104.3 million, an increase of 24.4%; and adjusted net income was $120.5 million, an increase of 24.9%.

Negative Updates

New Florida Operations Face Litigation and Turnaround Challenges

Management identified Florida’s litigation environment as a major red flag historically. The newly acquired Florida operations were described as almost all having below-average occupancy and substantial clinical and operational challenges, with problems across clinical performance, finances, and physical plant.

Company Guidance

The company increased annual 2026 earnings guidance to $7.94 to $8.02 per diluted share, up from previous guidance of $7.75 to $7.85, and raised the lower end of annual revenue guidance to $5.89 billion while maintaining the upper end at $5.92 billion; the midpoint of earnings guidance represents a 21.5% increase over 2025 and 45.1% growth over 2024. The guidance assumes diluted weighted average common shares outstanding of approximately 59.5 million, a tax rate of 25.0%, the inclusion of acquisitions closed and expected to close through the fourth quarter of 26, and management's expectations for reimbursement rates, with the primary exclusion coming from stock based compensation and amortization of system implementation cost.

The Ensign Group Risk Analysis

The Ensign Group disclosed 53 risk factors in its most recent earnings report. The Ensign Group reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

The Ensign Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:EGB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	85Outperform	$3.23B	22.83	12.94%	1.27%	7.19%	32.91%
ADUS	82Outperform	$2.34B	22.10	9.57%	―	15.88%	25.01%
PACS	74Outperform	$7.57B	28.12	27.15%	―	15.15%	101.51%
PNTG	60Neutral	$1.46B	44.32	9.51%	―	37.90%	15.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BKD	47Neutral	$2.48B	-17.95	405.63%	―	-4.42%	44.67%

* Healthcare Sector Average

Performance Comparison

DE:EGB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:EGB	The Ensign	165.40	10.63	6.87%
ADUS	Addus HomeCare Corporation	125.54	6.55	5.50%
BKD	Brookdale Senior Living Inc.	10.39	1.22	13.30%
NHC	National Healthcare	206.14	86.88	72.85%
PNTG	Pennant Group Inc	41.66	16.61	66.31%
PACS	PACS Group Inc	47.81	36.02	305.51%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

The Ensign Group AI Stock Analysis